Chawla Ashish K, Kachnic Lisa A, Clark Jeffrey W, Willett Christopher G
Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
Semin Oncol. 2003 Aug;30(4 Suppl 9):101-12. doi: 10.1016/s0093-7754(03)00276-8.
Combined modality therapy (CMT) with radiation therapy and chemotherapy plays an important role in the management of rectal cancer. Postoperatively, pelvic irradiation and 5-fluorouracil-based chemotherapy have been used to improve local control and survival for high-risk patients after local excision, as well as for patients undergoing abdominoperineal or low anterior resection. For patients treated preoperatively, CMT can also be used to facilitate sphincter-sparing surgery for distal rectal tumors. Preoperative CMT in conjunction with surgery and intraoperative radiation therapy has been useful for patients with locally advanced and recurrent rectal cancer as well. While chemotherapy has benefit for patients with stage III colon cancer above the peritoneal reflection, the role of CMT is less well defined. Retrospective reviews suggest improved local control and survival in subgroups of patients treated with postoperative radiation therapy and chemotherapy. Active areas of investigation in CMT for colorectal cancer include the integration of biologic predictors, radiation modulators, and novel systemic agents.
放射治疗和化疗相结合的综合治疗(CMT)在直肠癌的治疗中发挥着重要作用。术后,盆腔放疗和基于5-氟尿嘧啶的化疗已被用于提高局部切除术后高危患者以及接受腹会阴或低位前切除术患者的局部控制率和生存率。对于术前接受治疗的患者,CMT还可用于促进低位直肠癌的保肛手术。术前CMT联合手术和术中放疗对局部晚期和复发性直肠癌患者也很有用。虽然化疗对腹膜反折以上的III期结肠癌患者有益,但CMT的作用尚不太明确。回顾性研究表明,接受术后放疗和化疗的患者亚组的局部控制率和生存率有所提高。结直肠癌CMT的活跃研究领域包括生物预测指标、放射调节剂和新型全身药物的整合。